Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-5.26%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.99% | -76.55% | 46.81% | -12.05% | 69.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.99% | -76.55% | 46.81% | -12.05% | 69.24% |
| Cost of Revenue | -1.82% | -46.64% | 58.49% | -54.00% | -66.46% |
| Gross Profit | 20.02% | -83.56% | 43.94% | 12.53% | 1,955.15% |
| SG&A Expenses | -0.93% | -3.95% | 91.31% | -11.81% | -36.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.50% | -91.97% | -1.36% | -19.94% | -43.34% |
| Operating Income | 9.94% | 111.50% | 70.33% | 31.31% | 81.07% |
| Income Before Tax | -230.76% | 119.88% | -43.66% | -103.59% | 115.89% |
| Income Tax Expenses | -12.50% | -- | -- | -172.73% | 166.67% |
| Earnings from Continuing Operations | -232.05% | 119.88% | -43.66% | -103.58% | 115.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.05% | 119.88% | -43.66% | -103.58% | 115.79% |
| EBIT | 9.94% | 111.50% | 70.33% | 31.31% | 81.07% |
| EBITDA | 17.51% | 119.63% | 79.75% | 39.32% | 80.71% |
| EPS Basic | -178.97% | 105.39% | 93.41% | -100.16% | 100.36% |
| Normalized Basic EPS | -175.59% | 104.46% | 84.20% | 98.95% | 100.37% |
| EPS Diluted | -2,600.00% | 100.13% | 95.86% | -125.20% | 100.01% |
| Normalized Diluted EPS | -2,020.00% | 100.08% | 84.20% | -80.00% | 100.01% |
| Average Basic Shares Outstanding | 73.25% | 263.39% | 807.32% | 2,176.86% | 4,136.35% |
| Average Diluted Shares Outstanding | -92.83% | 19,262.12% | 807.32% | -86.79% | 102,280.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |